Sareum Holdings (AIM: SAR)

Last close As at 21/11/2026

GBP0.15

— 0.00 (0.00%)

Market capitalisation

GBP21m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases, which is approaching Phase II readiness and SDC-1802 for cancer (preclinical). Backed by positive Phase I data, SDC-1801 is undertaking advanced toxicology studies and capsule formulation optimisation in preparations for Phase II. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 63.5% economic interest), previously out licensed to Sierra Oncology.

Latest Insights

View More

Healthcare | Spotlight — flash

Sareum Holdings — Funding secured for next inflection

Healthcare | Spotlight — flash

Sareum Holdings — Funding the next value inflection

Healthcare | Comment

Sareum (AIM: SAR): Fundraising to support SDC-1801 progression

Sareum Holdings_resized

Share Price Chart

Market Data

Share Price GBP0.15
Market Cap GBP21m
52-Week High GBP0.39
52-Week Low GBP0.12
% Change 1M (12.1)
% Change 6M (29.3)
% Change 12M 7.4
Ave. Daily Volume 1yr 267,232

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

edison tv

Healthcare

Sareum Holdings – executive interview

Update

Healthcare

Sareum Holdings — SDC-1801 prepping to enter Phase II

Flash note

Healthcare

Sareum Holdings — New funding extends runway to Phase II

Flash note

Healthcare

Sareum Holdings — SDC-1801 records positive Phase Ia data

Flash note

Healthcare

Sareum Holdings — TYKing along steadily through the clinic

Flash note

Healthcare

Sareum Holdings — SDC-1801 on the way to the clinic

Flash note

Healthcare

Sareum Holdings — SDC-1801 CTA application hits a roadblock

Flash note

Healthcare

Sareum Holdings — SDC-1801 CTA filed in the UK

Update

Healthcare

Sareum Holdings — Approaching the clinic

edison tv

Healthcare

Sareum Holdings: Edison Open House Healthcare 2022

Flash note

Healthcare

Sareum Holdings — AGM produces key highlights

Update

Healthcare

Sareum Holdings — SDC-1801’s clinical plan modified

Flash note

Healthcare

Sareum Holdings — Fund raising to cushion pipeline risk

edison tv

Healthcare

Sareum Holdings – Edison Open House interview

Initiation

Healthcare

Sareum Holdings — Treading the TYK2 trail

QuickView

Healthcare

Sareum Holdings — Starting to tick the right boxes